4
MARKET OVERVIEW
Presents a concise view of industry direction, strategic priorities, and key indicators influencing market momentum.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Highlights the market structure, growth drivers, restraints, and near-term inflection points influencing performance.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITION RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.1
GDP TRENDS AND FORECAST
5.2.2
TRENDS IN THE OLIGONUCLEOTIDE THERAPEUTICS MARKET
5.2.3
TRENDS IN HEALTHCARE/PHARMA INDUSTRY
5.4.1
EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS
5.5.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT (2022-2024)
5.5.2
AVERAGE SELLING PRICE TREND, BY COUNTRY (2022-2024)
5.7
KEY CONFERENCES AND EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.9
INVESTMENT AND FUNDING SCENARIO
5.9.1
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
5.10
IMPACT OF 2025 US TARIFF – OLIGONUCLEOTIDE THERAPEUTICS MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS AND FUTURE APPLICATIONS
6.1.1
SOLID-PHASE SYNTHESIS
6.1.2
LIQUID-PHASE SYNTHESIS
6.1.3
ENZYMATIC OLIGO SYNTHESIS
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
POLYMERASE CHAIN REACTION (PCR)
6.2.2
NEXT-GENERATION SEQUENCING (NGS)
6.2.3
MICROARRAY ANALYSIS
6.3
ADJACENT TECHNOLOGIES
6.3.2
LIPID NANOPARTICLES
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.8
IMPACT OF AI/GEN AI ON THE OLIGONUCLEOTIDE THERAPEUTICS MARKET
6.8.1
TOP USE CASES AND MARKET POTENTIAL
6.8.2
CASE STUDIES OF AI IMPLEMENTATION IN THE OLIGONUCLEOTIDE THERAPEUTICS MARKET
6.8.3
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.8.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE OLIGONUCLEOTIDE THERAPEUTICS MARKET
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2
SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
10
OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY TYPE, 2023-2030 (USD MILLION)
10.2
ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS
10.3
SIRNA OLIGONUCLEOTIDE-BASED DRUGS
10.4
OTHER OLIGONUCLEOTIDE-BASED DRUGS
11
OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
11.5
OTHER ROUTES OF ADMINISTRATION
12
OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
12.2
NEUROLOGICAL DISORDERS
13
OLIGONUCLEOTIDE THERAPEUTICS MARKET, BY REGION, 2023-2030 (USD MILLION)
ASSESSMENT OF GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS THE KEY REGION AND ITS COUNTRIES
13.2.3
MACROECONOMIC OUTLOOK OF NORTH AMERICA
13.3.7
MACROECONOMIC OUTLOOK OF EUROPE
13.4.6
REST OF ASIA PACIFIC
13.4.7
MACROECONOMIC OUTLOOK OF ASIA PACIFIC
13.5.3
REST OF LATIN AMERICA
13.5.4
MACROECONOMIC OUTLOOK OF LATIN AMERICA
13.6.2
REST OF THE MIDDLE EAST
13.6.3
MACROECONOMIC OUTLOOK OF THE MIDDLE EAST
13.7.1
MACROECONOMIC OUTLOOK OF AFRICA
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
14.2
KEY PLAYERS STRATEGY/ RIGHT TO WIN
14.3
REVENUE ANALYSIS, 2022-2024
14.4
MARKET SHARE ANALYSIS,
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
14.5.5.1
COMPANY FOOTPRINT
14.5.5.2
REGION FOOTPRINT
14.5.5.3
MOLECULE FOOTPRINT
14.5.5.1
ROUTE OF ADMINISTRATION FOOTPRINT
14.6
COMPANY EVALUATION MATRIX: START-UPS/SMES,
14.6.1
PROGRESSIVE COMPANIES
14.6.2
RESPONSIVE COMPANIES
14.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
14.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
14.6.5.2
COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
14.8
VALUATION AND FINANCIAL METRICS
14.9
COMPETITIVE SCENARIO
14.9.3
OTHER DEVELOPMENTS
15.1.2
ALNYLAM PHARMACEUTICALS, INC.
15.1.3
SAREPTA THERAPEUTICS, INC.
15.1.4
ASTELLAS PHARMA INC.
15.1.5
JAZZ PHARMACEUTICALS PLC
15.1.7
NIPPON SHINYAKU CO., LTD.
NOTE: THE DETAILS ON BUSINESS OVERVIEW, FINANCIAL INFORMATION, PRODUCT PORTFOLIO, RECENT DEVELOPMENTS, MARKETSANDMARKETS VIEW WILL BE PROVIDED FOR ~25 COMPANIES. THESE DETAILS MIGHT NOT BE CAPTURED IN THE CASE OF UNLISTED COMPANIES. THE PROVIDED LIST OF P
16.1.1.1
KEY SOURCES OF SECONDARY DATA
16.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
16.1.2.1
BREAKDOWN OF PRIMARIES
16.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
16.2
MARKET SIZE ESTIMATION
16.2.1
OLIGONUCLEOTIDE THERAPEUTICS MARKET SIZE ESTIMATION
16.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
16.2.1.2
MNM REPOSITORY ANALYSIS
16.2.1.3
SECONDARY ANALYSIS
16.2.1.4
PRIMARY RESEARCH
16.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
16.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
16.3
MARKET GROWTH RATE PROJECTIONS
16.5
RESEARCH ASSUMPTIONS
16.6
RESEARCH LIMITATIONS AND RISK ASSESSMENT
17.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
AVAILABLE CUSTOMIZATIONS
Growth opportunities and latent adjacency in Oligonucleotide Therapeutics Market